Bill Text: NY A07285 | 2019-2020 | General Assembly | Amended


Bill Title: Requires health practitioners to discuss with patients the risks associated with certain pain medications before prescribing such medications; requires that for the first opioid analgesic prescription of a calendar year the prescribing physician shall counsel the patient on the risks of overdose.

Spectrum: Partisan Bill (Democrat 1-0)

Status: (Introduced - Dead) 2020-01-08 - referred to health [A07285 Detail]

Download: New_York-2019-A07285-Amended.html


                STATE OF NEW YORK
        ________________________________________________________________________
                                         7285--A
                               2019-2020 Regular Sessions
                   IN ASSEMBLY
                                     April 18, 2019
                                       ___________
        Introduced  by  M.  of  A. L. ROSENTHAL -- read once and referred to the
          Committee on Health -- committee  discharged,  bill  amended,  ordered
          reprinted as amended and recommitted to said committee
        AN  ACT  to amend the public health law, in relation to requiring health
          practitioners to discuss  with  patients  the  risks  associated  with
          certain  pain  medications before prescribing such medications; and in
          relation to opioid analgesic prescriptions
          The People of the State of New York, represented in Senate and  Assem-
        bly, do enact as follows:
     1    Section  1.  The  public health law is amended by adding a new section
     2  3309-b to read as follows:
     3    § 3309-b. Practitioner and patient discussions; opioid  prescriptions.
     4  1. Prior to issuing the initial prescription of a Schedule II controlled
     5  substance  for the treatment of pain or any other opioid drug which is a
     6  prescription drug for acute or chronic pain and again prior  to  issuing
     7  the  third prescription of the course of treatment, a practitioner shall
     8  discuss with the patient, or the patient's parent  or  guardian  if  the
     9  patient  is under eighteen years of age and is not an emancipated minor,
    10  the risks associated with the drugs being prescribed, including but  not
    11  limited to:
    12    (a)  the  risks of addiction and overdose associated with opioid drugs
    13  and the dangers of taking opioid drugs with alcohol, benzodiazepines and
    14  other central nervous system depressants;
    15    (b) the reasons why the prescription is necessary;
    16    (c) alternative treatments that may be available; and
    17    (d) the risks associated with the use of the drugs  being  prescribed,
    18  specifically  that  opioids  are  highly  addictive,  even when taken as
    19  prescribed, that there is a risk of developing a physical or  psycholog-
    20  ical  dependence  on  the  controlled  substance,  and that the risks of
    21  taking more opioids than prescribed, or  mixing  sedatives,  benzodiaze-
         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD10262-03-9

        A. 7285--A                          2
     1  pines   or  alcohol  with  opioids,  can  result  in  fatal  respiratory
     2  depression.
     3    2.  The  department  shall develop and make available to practitioners
     4  guidelines for the discussion required by this section.
     5    § 2. The public health law is amended by adding a new  section  3309-c
     6  to read as follows:
     7    § 3309-c. Opioid analgesic prescription. 1. For the first opioid anal-
     8  gesic  prescription of a calendar year that is greater than a one week's
     9  supply, the prescribing physician shall counsel the patient on the risks
    10  of overdose, and inform the patient of the  availability  of  an  opioid
    11  antagonist, including, but not limited to, naloxone.
    12    2.  For  the  purposes of this section, the following terms shall have
    13  the following meanings:
    14    (a) "Opioid analgesics" means the medicines  buprenorphine,  butorpha-
    15  nol,   codeine,  hydrocodone,  hydromorphone,  levorphanol,  meperidine,
    16  methadone, morphine, nalbuphine,  oxycodone,  oxymorphone,  pentazocine,
    17  propoxyphene as well as their brand names, isomers and combinations.
    18    (b) "Opioid antagonist" means an FDA-approved drug that, when adminis-
    19  tered,  negates  or  neutralizes in whole or in part the pharmacological
    20  effects of an opioid in the body. The opioid antagonist  is  limited  to
    21  naloxone  or  other  medications  approved  by  the  department for this
    22  purpose.
    23    § 3. This act shall take effect on the one hundred twentieth day after
    24  it shall have become a law. Effective immediately, the addition,  amend-
    25  ment and/or repeal of any rule or regulation necessary for the implemen-
    26  tation  of  this act on its effective date are authorized to be made and
    27  completed on or before such effective date.
feedback